Atlas Trials

Study Assessed the Safety and Efficacy of Eltrombopag in Chinese Refractory or Relapsed Severe Aplastic Anemia (SAA) Subjects.

Clinical trial NCT03988608 · COMPLETED

Trial details

NCT number
NCT03988608
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Aplastic Anemia
Start date
2019-12-09
Primary completion
2021-07-16
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.